But with treatments ranging from giving two drugs to five and even six drugs at once, it is hard for anyone to keep up. The latest debate is over whether to give patients a combination including two of a class of drugs known as protease inhibitors, which have proved to help keep the virus suppressed. There are currently four on the market and four more in experimental trials. Yes, dual protease inhibitor regimens will be among the choices for initial therapy. You don't want to play, necessarily, all your cards up front.
Some drug companies say otherwise.
He said ritonavir helped saquinavir work better. It's kind of a turbocharging effect. Then there is the newest class of drugs, known as non-nucleoside reverse transcriptase inhibitors, as well as a wide field of experimental drugs that fit none of the existing classes. Sun said this might not be wise. You've got to get a good crack.